Related Experiment Video

Updated: Jun 4, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Targeted therapies in systemic lupus erythematosus: successes, failures and future

Bevra H Hahn1

  • 1Correspondence to Dr Bevra H Hahn, Division of Rheumatology, David Geffen School of Medicine at UCLA, 1000 Veteran Avenue, Room 32-59, Los Angeles, CA 90095, USA. bhahn@mednet.ucla.edu

Annals of the Rheumatic Diseases
|February 23, 2011
PubMed
Abstract

Insights

Recent systemic lupus erythematosus (SLE) trials show mycophenolate mofetil and anti-BLyS (Benlysta) are effective treatments. These therapies help manage autoimmunity with comparable or improved outcomes and safety profiles.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease requiring effective treatment strategies.
  • Evaluating recent advancements in SLE therapeutics is crucial for improving patient outcomes.

Purpose of the Study:

  • To review recent phase III clinical trials in SLE patients.
  • To analyze treatment outcomes and mechanisms of action for novel immunosuppressive agents.

Main Methods:

  • Systematic review of prospective, randomized, controlled clinical trials in SLE.
  • Inclusion of published trials from the past 3 years and presented abstracts from 2008-2010.

Main Results:

  • Mycophenolate mofetil demonstrated efficacy comparable to cyclophosphamide with a similar safety profile.
  • Anti-BLyS (Benlysta) showed superiority over placebo when added to existing immunosuppression, without increased toxicity.
  • Trial outcomes were assessed using anchored composite indices, including the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).

Conclusions:

  • Mycophenolate mofetil and anti-BLyS are proven effective interventions for SLE management.
  • Anti-BLyS represents a significant advancement in biologic therapy for SLE.
  • Ongoing and pending trials will further elucidate the therapeutic landscape for SLE.

More Related Videos

Murine Bilateral Renal Lymphadenectomy06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.